

ASX Announcement

6th April 2020

Medibio's ilumen™ supporting the global workforce during COVID-19 health crisis

- Medibio's ilumen™ is a mental wellbeing solution that provides employers with a dashboard of de-identified data to better monitor and manage the mental wellbeing of their workforce.
- Medibio is currently responding to the heightened demand for ilumen™, driven by the global COVID-19 crisis and the social distancing requirements.
- Medibio is in discussions with previously announced partners¹, amongst others, regarding the accelerated implementation of ilumen™.

Melbourne, Australia and Minneapolis, MN – 6 April, 2020: Medibio Limited (MEB or the Company)(ASX: MEB)(OTCPINK: MDBIF), a mental health technology company pioneering the use of objective measures to aid in the early detection and screening of mental health conditions.

COVID-19 is having a profound effect on the Australian psyche and its economy, disrupting businesses of all sizes in every industry, and isolating individuals. The pressing need for mental health and wellness solutions has never been greater and is likely to increase for the foreseeable future.

As a consequence, Medibio is seeing heightened interest in and demand for its mental wellbeing solution, ilumen™. The Company is currently responding to this increased need by working closely with its current corporate clients and optimising prospective opportunities to maximise access to, implementation of, and support for ilumen™.

ilumen™ is a unique data-driven mental well-being program designed to aid in the evaluation and monitoring of the mental wellbeing of a workforce. For employers, ilumen™ provides a de-identified data-driven dashboard to better support and manage the mental wellbeing of its workforce and to help them assess the impact of their mental health programs. For employees, ilumen™ provides an early screening of mental health conditions such as stress and anxiety and provides them with a mental wellbeing 'snapshot' that they can use to make improvements over time.

Senior Vice President of Corporate Health at Medibio, Jennifer Solitario says: *"COVID-19 has changed everything about life and work as we know it. Attention to mental health in the workplace is more important now than ever before. We at Medibio are seeing a heightened interest and demand for ilumen™ both in Australia and internationally, and we are responding accordingly. Medibio's ilumen™ team here in Australia and the USA are working to ensure that ilumen™ is made available to those corporations and their employees as easily and as efficiently as possible"*.

¹ ASX Announcement dated – 25 March 2020 - <https://www.asx.com.au/asxpdf/20200325/pdf/44qch5qm1f62fd.pdf>
 ASX Announcement dated – 21 October 2019 <https://www.asx.com.au/asxpdf/20191021/pdf/449p52m7yv9v.pdf>

– ENDS –

This announcement is authorised for release to the market by the Board of Directors of Medibio Ltd.

About Medibio Limited

Medibio (ASX: MEB) (OTCPINK: MDBIF) is a mental health technology company pioneering the use of objective measures to aid in the early detection and screening of mental health conditions. Through their Corporate Health product, the Company offers mental well-being solutions for businesses and are also developing products to serve the healthcare provider market. The company was founded in Australia, with offices located in Melbourne (Vic) and Minneapolis (MN). Medibio is listed on the Australian Securities Exchange Ltd and trades on the OTC Pink Open Market. Investors can find additional information on www.otcmarkets.com and www.asx.com.au.

Further Information:	Website: www.medibio.com.au
Australian Investor Enquiries: Peter Taylor NWR Communications peter@nwrcommunications.com.au T: +61 (0) 412 036 231	